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Abstract
Introduction Subjects with autosomal dominant poly-
cystic kidney disease (ADPKD) who were taking tolvaptan
experienced aminotransferase elevations more frequently
than those on placebo in the TEMPO 3:4 (Tolvaptan
Efficacy and Safety in Management of Autosomal Domi-
nant Polycystic Kidney Disease and its Outcomes) clinical
trial.
Methods An independent, blinded, expert Hepatic Adju-
dication Committee re-examined data from TEMPO 3:4
and its open-label extension TEMPO 4:4, as well as from
long-term ([14 months) non-ADPKD tolvaptan trials,
using the 5-point Drug-Induced Liver Injury Network
classification.
Results In TEMPO 3:4, 1445 subjects were randomized
2:1 (tolvaptan vs. placebo) and 1441 had post-baseline
assessments of hepatic injury. Sixteen patients on tolvaptan
and one on placebo had significant aminotransferase ele-
vations judged to be at least probably related to study drug.
No association with dose or systemic exposure was found.
Two of 957 subjects taking tolvaptan (0.2 %) and zero of
484 taking placebo met the definition of a Hy’s Law case.
One additional Hy’s Law case was identified in a TEMPO
4:4 subject who had received placebo in the lead study. The
onset of a hepatocellular injury occurred between 3 and
18 months after starting tolvaptan, with gradual resolution
over the subsequent 1–4 months. None of the events were
associated with liver failure or chronic liver injury/dys-
function. No imbalance in hepatic events was observed
between tolvaptan and placebo in lower-dose clinical trials
of patients with hyponatremia, heart failure, or cirrhosis.
Conclusions Although hepatocellular injury following
long-term tolvaptan treatment in ADPKD subjects was
infrequent and reversible, the potential for serious irre-
versible injury exists. Regular monitoring of transaminase
levels is warranted in this patient population.
Key Points
In patients with autosomal dominant polycystic
kidney disease (ADPKD), long-term treatment with
tolvaptan can rarely cause severe and potentially life-
threatening liver injury.
This injury is typically hepatocellular, occurs
between 3 and 18 months after starting tolvaptan,
and resolves within 4 months after stopping the drug.
A risk of similar liver injury was not detected
following exposure to tolvaptan in non-ADPKD
patients.
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1 Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is an inherited disorder characterized by the appearance
and slow growth of fluid-filled cysts primarily in the kid-
neys, but also in the liver and other organs [1, 2]. Over
time, the expanding cysts physically displace and obstruct
renal tubules, blood vessels and lymphatics, as well as
promote apoptosis, atrophy and fibrosis of the renal par-
enchyma, leading to progressive renal failure [3]. ADPKD
was responsible for 2.6 % of patients on dialysis and 9.9 %
of patients receiving renal transplants in the USA in 2012
[4].
Studies of animal models implicate the antidiuretic
hormone arginine vasopressin and its secondary messenger
30,50-cyclic adenosine monophosphate (cAMP) as promot-
ers of kidney-cyst cell proliferation and luminal fluid
secretion [5, 6]. In early animal models the suppression of
vasopressin release by vasopressin V2-receptor inhibition
slowed disease progression [7, 8]. Because tolvaptan is a
V2 receptor antagonist, its use in treating ADPKD was
investigated. In the pivotal TEMPO 3:4 (Tolvaptan Effi-
cacy and Safety in Management of Autosomal Dominant
Polycystic Kidney Disease and its Outcomes) trial (Clini-
calTrials.gov identifier: NCT00428948 [24]), long-term
treatment with tolvaptan was associated with favorable
outcomes in subjects with early ADPKD. These favorable
outcomes included lower rate of growth in total kidney
volume (2.8 vs. 5.5 %; p\ 0.001) and slower decline in
kidney function [reciprocal of the serum creatinine level,
-2.61 vs. -3.81 (mg per mL)-1 per year; p\ 0.001] [9].
TEMPO 3:4 and its extension trial TEMPO 4:4 (Clini-
calTrials.gov identifier: NCT01214421 [25]) were contin-
uously monitored by an Independent Data Monitoring
Committee (IDMC) that assessed overall safety, including
hepatic function and injury. During the course of continued
monitoring of the TEMPO trials, the IDMC recommended
increasing the frequency of liver monitoring in the TEMPO
4:4 extension study, from every 6 months to every
3 months. Upon unblinding of the TEMPO 3:4 database, an
imbalance in hepatic injury, defined as alanine amino-
transferase (ALT) [3 times the upper limit of normal
(ULN), was observed for subjects receiving tolvaptan
(4.4 %) relative to placebo (1.0 %). To assess the risk of
hepatotoxicity, an independent, blinded, expert Hepatic
Adjudication Committee (HAC) re-examined subject-level
data from all ADPKD clinical trials, as well as data from
non-ADPKD subjects who had received long-term
tolvaptan therapy in other clinical trials, including patients
with hyponatremia [syndrome of inappropriate anti-diuretic
hormone release (SIADH)], heart failure, and cirrhosis.
The results of this analysis are presented here.
2 Methods
2.1 Subjects
The safety databases reviewed here were generated in
clinical trials that examined the efficacy and safety of
tolvaptan in the treatment of ADPKD. The vast majority of
included subjects were from the pivotal, randomized, pla-
cebo-controlled TEMPO 3:4 trial (NCT00428948 [24]) [9]
and its open-label extension TEMPO 4:4 (NCT01214421
[25]). To be eligible for inclusion in TEMPO 3:4, all
subjects had to have an image-confirmed diagnosis of
ADPKD, total kidney volume C750 mL and an estimated
creatinine clearance rate C60 mL/min. 1445 subjects were
enrolled (tolvaptan, 961; placebo, 484) and 1441 had at
least one post-baseline assessment of hepatic injury.
Tolvaptan was administered twice daily, starting at a
morning/afternoon dose of 45/15 mg and titrated weekly to
60/30 mg and 90/30 mg based on tolerability; subjects
could down-titrate at any time to as low as the starting dose
(45/15 mg). Subjects were treated for 36 months or until
early discontinuation. In TEMPO 4:4, 871 subjects from
the lead TEMPO 3:4 trials (tolvaptan, 557; placebo, 314),
received open-label tolvaptan at their highest tolerated dose
for a minimum of 24 additional months. The study drug
was discontinued when pre-determined criteria were met.
Re-challenge was conducted on an individual basis.
To provide further context for this analysis, safety
databases from the non-ADPKD clinical trials evaluating
the efficacy and safety of tolvaptan in subjects with heart
failure or hyponatremia (etiologies included SIADH, heart
failure, and cirrhosis) were also examined. In total, 6155
subjects were enrolled (tolvaptan, 3403; placebo, 2752)
across all non-ADPKD trials, and 4664 subjects (tolvaptan,
2414; placebo, 2250) were enrolled in long-term placebo-
controlled trials. All trials were sponsored by Otsuka
Pharmaceuticals.
2.2 Evaluation of Drug-Induced Serious
Hepatotoxicity (eDISH) Assessments
The Evaluation of Drug-Induced Serious Hepatotoxicity
(eDISH) approach was used to efficiently visualize poten-
tial hepatocellular injury in the large subject populations
examined in this study and to supply supportive data for the
adjudication process. This is a graphical methodology in
which the log of the peak serum ALT concentration is
plotted for each subject along the x-axis and the log of peak
total serum total bilirubin (BT) concentration is plotted
along the y-axis [10]. Four quadrants on the eDISH plot are
defined by lines at 3 9 ULN for ALT and 2 9 ULN for
BT. The upper-right quadrant is the Hy’s Law quadrant,
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although patients may also appear there due to cholestatic
liver injury. To separate out these latter confounders, US
FDA guidance defines a subject in the upper-right quadrant
as having severe drug-induced liver injury (DILI) when the
serum alkaline phosphatase is\2 9 ULN [11].
An excess of subjects in the lower-right quadrant for a
study drug relative to placebo also indicates a drug that
may be capable of causing liver injury, even when exam-
ination of the Hy’s Law quadrant is unrevealing [11]. This
reflects the fact that ALT is a more sensitive indicator of
hepatocellular injury than BT and that increases in ALT
may occur before or without accompanying rises in serum
bilirubin [12]. Subjects discovered to have elevated serum
ALT may be discontinued from treatment before the injury
progresses to the point of bilirubin elevations. Finally, an
excess of patients in the upper-left quadrant for a study
drug relative to placebo is generally observed in drugs
associated with cholestatic liver reactions, or patients with
Gilbert’s syndrome or other causes of isolated
hyperbilirubinemia.
2.3 Adjudication of Hepatic Safety Signals
The HAC consisted of four expert hepatologists (PBW,
JHL, NK, and DHA) who reviewed safety data from
ADPKD and non-ADPKD (hyponatremia, heart failure,
and cirrhosis) tolvaptan trials. Five general categories of
adverse events were identified for further adjudication:
1. Category 1 A non-serious treatment-emergent event
leading to discontinuation of treatment or any serious
treatment-emergent adverse event matching a lower
level term in any one of the following hepatic standard
MedDRA1 queries (SMQs):
(a) cholestasis and jaundice of hepatic origin,
(b) hepatic failure, fibrosis, and cirrhosis and other
liver damage-related conditions,
(c) non-infectious hepatitis,
(d) liver-related investigations, signs, and symptoms,
(e) liver-related coagulation and bleeding
disturbances.
2. Category 2 ALT[3 9 ULN and BT[2 9 ULN.
3. Category 3 aspartate aminotransferase (AST)[3 9
ULN and BT[2 9 ULN.
4. Category 4 ALT or AST[5 9 ULN.
5. Category 5 BT[2 9 ULN.
In cases where ULN could not be obtained, 40 IU/L and
1 mg/dL (17 lM/L) were used for ALT and BT, respec-
tively. Laboratory evaluations were completed during the
TEMPO 3:4 trial at baseline, 3 weeks, 4 months, and every
4 months thereafter.
For causality assessment, the four hepatologists com-
prising the HAC agreed to utilize ‘‘expert opinion’’ rather
than a structured scoring instrument [e.g., Roussel Uclaf
Causality Assessment Method (RUCAM)] [13]. The com-
mittee assessed causality of all adjudicated events based on
co-morbid conditions, concomitant medication use, onset,
offset, and dose relationship. Events of interest were allo-
cated into the following five causality groups, as defined by
the Drug-Induced Liver Injury Network [14, 15]: ‘‘defi-
nite’’, i.e., evidence that the drug is causing the injury is
beyond reasonable doubt; ‘‘highly likely’’, i.e., evidence
that the drug is causing the injury is clear and convincing
but not definite; ‘‘probable’’, i.e., the preponderance of
evidence supports the link between the drug and liver
injury; ‘‘possible’’, i.e., the evidence for the drug causing
the injury is equivocal but present; and ‘‘unlikely’’, i.e.,
evidence is available that an etiological factor other than
the drug caused the injury. Cases judged ‘‘not classifiable’’
in regard to the role of the study drug occurred when the
data were insufficient to render an opinion. Such situations
arose when other confounding factors were present (e.g.,
diseases or other medications) but details could not be
provided for the intensity/dose and timing of the underly-
ing conditions (e.g., congestive heart failure, ischemia,
multiple drug administration, underlying liver disease).
Insufficient data were infrequently encountered [0/98 (0 %)
ADPKD cases and 5/52 (10 %) non-ADPKD cases], but
when it was the consensus opinion, it was always in cases
with significant underlying diseases other than ADPKD.
The four hepatologists on the committee performed their
assessments independently and without knowledge of
treatment assignment. If committee members did not arrive
at an identical independent causality score for a particular
case, the case was discussed further in conference and a
final causality determination was achieved by consensus,
although majority rule was used in rare instances where
consensus could not be achieved.
Because TEMPO 4:4 was ongoing at the time the
adjudication was initiated, the committee performed two
rounds of adjudication, one with a cut-off date of 31 March
2012 to provide initial feedback and guide future treatment
regimens, and a later one with a cut-off date of 31 March
2015. The selection criteria for adjudicated cases were
identical during the two periods, with the exception that
Category 5 (BT[2 9 ULN) was not employed between
October 2012 and February 2014. This change was
prompted by discussions among the hepatology experts,
who agreed that a patient with an isolated elevated serum
1 MedDRA (The Medical Dictionary for Regulatory Activities)
terminology is the international medical terminology developed under
the auspices of the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH). MedDRA trademark is owned by the Interna-
tional Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) on behalf of ICH.
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bilirubin in the absence of the other selection criteria was
not a safety concern.
3 Results
3.1 Subjects
The duration of exposure to tolvaptan in all of the ADPKD
studies is shown in Table 1. Up until the first cut-off date
(31 March 2012), 1581 subjects had received tolvaptan
therapy, of whom 838 (53.0 %) and 814 (51.5 %) had
received the drug for 18 and 24 months, respectively. By
the 31 March 2015 data capture, 1636 ADPKD subjects
had received tolvaptan, of whom 1330 (81.3 %) and 1266
(77.4 %) had been treated for 18 and 24 months, respec-
tively. Clinical demographics for subjects adjudicated as
probable or higher were comparable with the total popu-
lation from the pivotal TEMPO 3:4 study [mean (standard
deviation) age: 42 (5) vs. 39 (7) years; n (%) male: 12
(40 %) vs. 746 (52 %)].
3.2 Hepatic Events in the TEMPO 3:4 Study
The pivotal TEMPO 3:4 trial included 957 ADPKD sub-
jects who received tolvaptan and 484 who received pla-
cebo. An imbalance between tolvaptan- and placebo-
treated subjects with ALT[3 9 ULN and BT\2 9 ULN
was also observed in TEMPO 3:4 [40/957 (4.4 %) vs.
5/484 (1.0%), respectively] (Fig. 1a, lower-right quadrant).
No imbalance in ALT[3 9 ULN between treatment
groups was evident at baseline [3/946 (0.32 %) vs. 1/479
(0.21 %), respectively]. Using adjudication criteria, 35
tolvaptan- and 11 placebo-treated subjects were investi-
gated by the independent HAC (Table 2). The likelihood
that an event was caused by study medication was assessed
as probable or higher in 17 of these subjects, of whom 16
had received tolvaptan and one had received placebo. The
presence of possible confounding diagnoses, including risk
factors for viral hepatitis, autoimmune hepatitis, fatty liver
disease, alcohol consumption, and concomitant use of
medications with potential for idiosyncratic transaminase
elevations, may have exacerbated the tolvaptan-related
hepatotoxicity in some subjects.
Two of the probable events in the tolvaptan group [2/
957 (0.2 %)] and zero in the placebo group [0/484 (0 %)]
met Hy’s Law laboratory criteria (ALT[3 9 ULN and BT
[2 9 ULN) (Fig. 1a, upper-right quadrant).
The two Hy’s Law cases had received the highest dose
of tolvaptan administered in the study (120 mg/day split
into morning/evening doses of 90/30 mg). In both cases
ALT and BT returned to \3 3 ULN and \2 3 ULN,
respectively, following withdrawal from tolvaptan (Fig. 2).
Although both Hy’s Law cases occurred at the highest
administered dose, subjects adjudicated as probable or
higher were generally distributed across all doses and
exposures, with no significant difference in the area under
the concentration–time curve (p = 0.7543), suggesting no
clear dose dependence (Fig. 3). This finding is supported
by a Fisher exact test that failed to identify a statistical
relationship between dose and hepatotoxicity
(p = 0.3464). While no association with dose of exposure
was found, additional research has been initiated to further
investigate the role of dose and exposure on the risk of
hepatic injury.
3.3 Open-Label Extension Study
Up until the cut-off date of the first adjudication period,
nine of 846 (1.11 %) subjects receiving open-label
tolvaptan met hepatic adjudication criteria. One subject
met Hy’s Law laboratory criteria (Table 2) and eight sub-
jects (0.95 %) experienced ALT/AST elevations
[3 9 ULN, with BT\2 9 ULN. Among these nine sub-
jects with ALT[3 9 ULN, the liver signal was attributed
to tolvaptan (causality assessed as probable or higher) for
the Hy’s Law subject and four of eight subjects with ALT
elevations; all had received placebo during TEMPO 3:4
prior to crossing over to tolvaptan in TEMPO 4:4.
During the second adjudication period, 31 additional
cases from the extension study were referred to the HAC
(Table 2). Of these, four were adjudicated as highly likely
(n = 1) or probable (n = 3) for tolvaptan causality. Two of
the previous four subjects had received tolvaptan in the
pivotal study and two had received placebo. No new Hy’s
Law cases were identified in the second reporting period.
3.4 Hepatic Events in the Non-Autosomal Dominant
Polycystic Kidney Disease Trials
In total, 2414 subjects received tolvaptan and 2250 sub-
jects received placebo in the long-term non-ADPKD trials
(hyponatremia, heart failure, and cirrhosis). Of these, 589
Table 1 Extent of exposure to tolvaptan: all autosomal dominant







C1 day 1581 (100) 1588 (100)
C6 months 1017 (64.3) 1509 (95.0)
C12 months 886 (56.0) 1368 (86.1)
C18 months 838 (53.0) 1275 (80.3)
C24 months 814 (51.5) 1195 (75.3)
C36 months 661 (41.8) 962 (60.6)
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were enrolled in clinical studies that exposed subjects to
tolvaptan for at least 14 months, the majority of whom
had heart failure (553). No evident imbalance between
tolvaptan- and placebo-treated subjects was observed in
the upper- or lower-right quadrants of eDISH plots
(Fig. 1b–e). Given the similar number of subjects in both
groups that experienced elevations in ALT [3 9 ULN,
the HAC decided to adjudicate only subjects with higher
degrees of hepatic dysfunction as reflected by ALT
[5 9 ULN and concomitant bilirubin[3 9 ULN. This
amounted to 28 cases across all three subject populations.
Only one of the 28 cases was judged to be possibly due to
study drug, whereas the remaining 27 cases were con-
sidered to be unlikely. After unblinding the treatment
assignment, the single possible case was found to have
received placebo.
3.5 Identifying a Signature Pattern
In TEMPO 3:4, the 16 cases with ALT elevations
[3 9 ULN that were attributable to tolvaptan (probable or
highly likely) were detected between 3 and 18 months after
initiation (Fig. 4). For the two Hy’s Law cases, ALT eleva-
tions[3 9 ULNfirst occurred between 5 and 9 months post
initiation of tolvaptan. All 35 cases adjudicated in the
tolvaptan group returned to B3 9 ULN. The majority of
subjects who had discontinued tolvaptan (14/35) returned to
B3 9 ULNwithin 40 days, whereas themajority of subjects
Fig. 1 Evaluation of drug-induced serious hepatotoxicity (e-DISH)
plots for a ADPKD (TEMPO 3:4); b non-ADPKD subjects; and (c–
e) non-ADPKD subjects by etiology. Peak ALT (x-axis) versus peak
total bilirubin (y-axis). Vertical lines correspond to 3 9 ULN for
ALT. Horizontal lines correspond to 2 9 ULN for BT. Subjects in the
lower-left quadrant are relatively normal and subjects meeting Hy’s
laboratory criteria are shown in the upper-right quadrant. ADKPD
autosomal dominant polycystic kidney disease, ALT alanine amino-
transferase, BT total bilirubin, PLC placebo, TLV tolvaptan, ULN
upper limit of normal
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who had continued therapy (21/35) returned to B3 9 ULN
within 120 days (data not shown). There was no correlation
between the height of the peak serum ALT and duration of
the ALT elevation[3 9 ULN (data not shown).
The timing of the onset of the liver injury was not
always known; the first blood sample obtained by the
central laboratory was at the end of the 3-week titration
period. Per protocol, the next assessment of liver
Table 2 Adjudication results
for subjects meeting criteria for
adjudication based on Drug-
Induced Liver Injury Network
criteria
Clinical trial DILIN criteria
Definite Highly likely Probable Possible Unlikely
First adjudication period (cut-off: 31 March 2012)
TEMPO 3:4
Tolvaptan 0 1 15 10 9
Placebo 0 0 1 2 8
TEMPO 4:4
Placebo ? tolvaptan 0 2 3 0 2
Tolvaptan ? tolvaptan 0 0 0 1 1
Other ADPKD studies
Tolvaptan 0 0 2 1 2
Second adjudication period (cut-off: 31 March 2015)
TEMPO 4:4 extensiona
Placebo ? tolvaptan 0 1 1 3 6
Tolvaptan ? tolvaptan 0 0 2b 7 10
Other ADPKD studies
Tolvaptan 0 0 2 2 2
Placebo 0 0 0 1 0
ADKPD autosomal dominant polycystic kidney disease, DILIN Drug-Induced Liver Injury Network
a In addition, there was one subject (tolvaptan ? tolvaptan) that had insufficient data for adjudication
b Both subjects received a modified release formulation of tolvaptan for 8 weeks prior to enrolling in
TEMPO 4:4
Fig. 2 Patterns of hepatic transaminase/total bilirubin elevations in
the three Hy’s Law cases in TEMPO 3:4 and its open-label extension
study TEMPO 4:4. Cases A and B are from TEMPO 3:4, and case C
was from TEMPO 4:4 (a prior placebo subject from TEMPO 3:4).
Additional information on each case study is presented in Sect. 3.
Gray shading in the background represents periods of dosing; white
lines correspond to dosing interruptions. ALP alkaline phosphatase,
ALT alanine aminotransferase, AST aspartate aminotransferase, BT
total bilirubin, ULN upper limit of normal
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chemistries was not until the 4-month visit (Fig. 4), but
local laboratory values were sometimes available prior to
this date. Examples of liver enzyme patterns from repre-
sentative cases are shown in Fig. 5. Nearly half of the
patients (10/21) were able to continue therapy with ALT
levels that remained \3 9 ULN after recovery, whereas
the remaining patients (11/21) exhibited rapid transaminase
elevations following re-challenge with therapy that led to
discontinuation, but subsequently returned to normal over
1–4 months. No patient who was re-challenged in this
manner met criteria for acute liver failure.
Based on the characteristics of the positively adjudicated
cases, the HAC suggested a potential signature pattern for
the observed events defined as development of acute hep-
atocellular injury with onset between 3 and 18 months after
starting tolvaptan therapy.
3.6 Hy’s Law Case Studies
3.6.1 Case 1
Eight months after initiating tolvaptan treatment in
TEMPO 3:4, a 34-year-old woman presented with jaun-
dice and increased BT, ALT, and AST (Fig. 2a). She had
consumed a single 8 g dose of Augmentin between 2
and 3 months before liver injury was detected.
Augmentin is a relatively frequent cause of liver injury
and characteristically presents as a mixed hepatocellu-
lar/cholestatic reaction, often associated with evidence of
immunoallergy (e.g., rash, fever, eosinophilia) [16].
Hepatocellular injury is a less common presentation, but
is more frequently observed in patients under 45 years. In
the HAC’s experience, there have been no reports of
Augmentin causing clinically important liver injury after
a single dose (albeit an overdose in this case). Also, the
latency to presentation was long (typically 1–2 months
after the start of treatment). It was noted that the timing
of the event was consistent with the tolvaptan signature
presentation; however, resolution following tolvaptan
discontinuation was more rapid than is characteristic. The
event was adjudicated as probably related to tolvaptan by
blinded consensus.
3.6.2 Case 2
A 45-year-old woman presented with complaints of nausea
and stomach discomfort and elevations in ALT and AST
liver enzymes 4 months after initiating tolvaptan treatment
in TEMPO 3:4. Transaminase elevations were resolving on
continued treatment when she experienced worsening
nausea and a more severe injury at around 7 months,
resulting in hospitalization (Fig. 2b). She was treated with
prednisone during the resolution of the second peak, raising
the possibility of autoimmune hepatitis. She experienced
bleeding into her liver cysts, which suggested the presence
of coagulopathy. It is unclear if she remains on immuno-
suppression. The event was adjudicated as probably related
to tolvaptan by blinded consensus.
3.6.3 Case 3
A 44-year-old woman received placebo in TEMPO 3:4
prior to the open-label study (Fig. 2c). She developed
nausea, abdominal pain, and jaundice and was hospitalized
with hepatocellular injury 3 months after initiating
tolvaptan treatment. Liver biopsy (performed by the
investigator at the request of a consulting hepatologist
30 days after the event) showed ‘‘cytolytic hepatitis’’ with
evidence of centrilobular necrosis, suggestive of DILI. The
pattern of liver injury fit the clinical signature, and the
event was adjudicated as highly likely related to tolvaptan
by blinded consensus.
3.6.4 Summary of Cases
In all three Hy’s Law cases, ALT and BT returned to
normal with no chronic liver injury reported following
permanent discontinuation of tolvaptan.
Fig. 3 Estimated tolvaptan exposure in TEMPO 3:4 for subjects
adjudicated as probable or higher. Exposures at each of the three
doses for all subjects with measurable tolvaptan concentrations are
represented by box and whisker plots which summarize daily steady-
state exposure, AUC, predicted using individual empirical Bayesian
estimates from the population pharmacokinetic model at the individ-
ual modal dose. Tolvaptan exposures at the dose taken at the time of
the onset of the first hepatic event, for each of the subjects adjudicated
as probable or higher is represented as an ‘‘9’’. Hy’s Law cases are
shown as arrows. Whiskers represent the 10th and 90th percentiles,
black dots represent the 5th and 95th percentiles. AUC area under the
plasma concentration–time curve
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4 Discussion
No cases of acute liver failure have been reported in clin-
ical trials of tolvaptan in ADPKD, and all subjects expe-
riencing hepatic injury have recovered. Nonetheless,
tolvaptan treatment was associated with elevations in
serum aminotransferases exceeding 3 9 ULN in subjects
with ADPKD. This finding alone is not considered to be a
reliable liver safety signal [11], but three tolvaptan-treated
subjects in the TEMPO 3:4 clinical trial and its open-label
extension were confirmed to have met criteria for Hy’s
Law (ALT[3 9 ULN and BT[2 9 ULN). Based on
FDA guidance [11], the identification of Hy’s Law cases
indicates that tolvaptan has the potential to cause hepatic
injury capable of progressing to liver failure in patients
with ADPKD. The apparent rarity of hepatic injury
observed with tolvaptan has all the characteristics of an
idiosyncratic reaction, suggesting the vast majority of
patients should be able to receive long-term treatment
without risk of liver injury.
A signature presentation of liver injury was discerned
from the reviewed data. Tolvaptan-associated hepatocellular
injury had an onset between 3 and 18 months, with little
evidence of similar events before or after this period of
apparent susceptibility. The injury typically progressed by
biochemical criteria for a median of 28 [interquartile range
(IQR) 15–50] days after discontinuation of treatment, and
resolved slowly over a median of 46 (IQR 32.5–70) days.
Liver biopsies were obtained in only four of 25 (16 %)
subjects adjudicated as probable or higher and, as is typical
with idiosyncratic DILI, no pathonomonic features were
evident [17].
A number of patients were re-challenged with tolvaptan
after elevated ALT values subsided. Approximately half of
these subjects were able to tolerate the drug when it was re-
introduced, suggesting that a form of adaptation or drug
tolerance occurs. However, the other half experienced
rapid ALT elevations upon re-exposure (positive re-chal-
lenge) and tolvaptan treatment had to be permanently
withdrawn. The more rapid recurrence of injury upon re-
Fig. 4 Time to first elevation of
alanine aminotransferase to
[3 9 upper limit of normal in
adjudicated subjects. a TEMPO
3:4: the apparent window of
susceptibility is shown as
shaded in yellow. All of the
tolvaptan cases adjudicated as
probable or higher are shown as
green arrows and the two Hy’s
Law cases are shown as red
arrows. b TEMPO 4:4: the Hy’s
Law case is shown as a red
arrow. TLV tolvaptan
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exposure may indicate an adaptive immune mechanism and
studies are underway to search for possible human leuko-
cyte antigen (HLA) risk alleles as have been demonstrated
for delayed DILI caused by other agents, including xime-
lagatran, lumiracoxib, and lapatinib [18–20].
Following a recommendation from the TEMPO Steering
Committee to increase the frequency of monitoring to
monthly, no additional Hy’s Law cases have been identi-
fied to date (n = 1275 subjects exposed for C18 months)
(Table 1), further lowering the incidence of potential liver
failure to approximately 1:4000. It should be noted that
since liver chemistry monitoring was relatively infrequent
in TEMPO 3:4 and its open-label extension, more frequent
monitoring is expected to further lower the risk of liver
failure. In some cases, liver injury did progress for weeks
after stopping drug treatment, followed by slow resolution,
and it seems unlikely that the risk of serious liver injury
could be eliminated solely by more frequent monitoring.
While no additional Hy’s cases have been identified since
implementation of a comprehensive monitoring program
consisting of monthly liver enzyme testing went into effect,
the number of additional patients treated does not provide
sufficient power to eliminate the possibility of another Hy’s
case from occurring.
Fig. 5 Patterns of hepatic transaminases/total bilirubin elevations in
cases representative of the signature profile. Case A represents a
subject whose ALT continued to rise transiently post-tolvaptan
discontinuation prior to a return to\1 9 ULN (a). Cases B and C
experienced similar ALT elevations to case A; however, both
observed an immediate elevation in ALT upon re-challenge with
tolvaptan (b and c). Both subjects subsequently returned to
\1 9 ULN upon discontinuation. Cases D and E are representative
examples of subjects whose ALT normalized while on tolvaptan
(d and e). Gray shading in the background represents periods of
dosing, darker shades of gray represent higher doses of tolvaptan;
white lines correspond to dosing interruptions. ALP alkaline phos-
phatase, ALT alanine aminotransferase, AST aspartate aminotrans-
ferase, BILI bilirubin, ULN upper limit of normal
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Of note, there was no evidence of a similar liver safety
signal or signature presentation observed among subjects
with cirrhosis, congestive heart failure, or hyponatremia
exposed to tolvaptan in non-ADPKD clinical trials. This
was a surprising finding, as the expectation might be that
patients with liver disease or severe congestive heart failure
would be more susceptible to DILI. The explanation is
unlikely due to sample size, since the number of subjects
treated for at least 14 months in the non-ADPKD popula-
tions (n = 589) was not grossly different from the corre-
sponding number of ADPKD subjects (n * 860).
Although the dose of tolvaptan received by the non-
ADPKD population (single daily dose up to 60 mg/day)
was lower than that received by most subjects in the
ADPKD trials (split daily dose up to 120 mg/day), the
overall exposure for most chronic heart failure subjects was
similar to subjects receiving a split dose of 45/15 mg/day
in the ADPKD population (data on file). It is possible that
patients with ADPKD may be more susceptible to tolvap-
tan-associated liver injury than other patient populations
due to an unknown feature of disease pathology. In this
regard, it should be noted that the most common extra-
renal manifestation of ADPKD is polycystic liver disease,
which is characterized by the presence of multiple hepatic
cysts originating from biliary ducts and peribiliary glands
[21]. In the CRISP (Consortium for Radiologic Imaging
Studies of Polycystic Kidney Disease) study, hepatic cysts
were observed in 58 % of 15- to 24-year-olds, 85 % of 25-
to 34-year-olds, and 94 % of 35- to 46-year-olds with
ADPKD [22]. While imaging to document the presence of
hepatic cysts was not included in the study protocols, more
than 60 % of subjects in TEMPO 3:4 had liver cysts as
determined by medical history or a retrospective review of
their study MRIs. While it was not possible to correlate the
presence of hepatic cysts with susceptibility to tolvaptan-
associated liver injury in this study, 76 % of subjects
adjudicated as probable or higher in TEMPO 3:4 and
TEMPO 4:4 demonstrated some degree of hepatic cyst
burden. It should also be noted that 18 of 30 (60 %) of
subjects adjudicated as probable or higher and all three
Hy’s law cases occurred in women, but it remains unknown
whether this reflects true sex-specific differences.
Several risk-management strategies seem plausible for
mitigating the potential for irreversible liver damage in the
setting of long-term tolvaptan treatment for ADPKD,
including more frequent liver testing at monthly intervals
through the window of observed susceptibility. In addition,
a personalized medicine approach might be feasible. Tar-
geted genetic studies are currently underway to examine
the potential role of the HLA genotype, as are studies to
determine if subjects with PKD1 or PKD2 have similar
risks for hepatocellular injury [23]. Alternatively, the
observed liver injury may have a metabolic or mechanistic
etiology. To address this possibility, drug-metabolizing
enzymes, drug transporters, stress response proteins,
mitochondrial markers, extracellular vesicle trafficking,
and biliary disposition are all being examined. Finally,
large-scale screening methodologies are being employed to
detect other potential biomarkers that might be used to
identify the rare ADPKD patient susceptible to tolvaptan-
mediated liver injury.
5 Study Limitations
This was a retrospective analysis. The interval between
protocol-driven assessments of liver chemistries changed
after an interim analysis by the Data and Safety Monitoring
Board but remained relatively long in these studies. This
limited the ability to time the onset of injury and it is also
possible that transient but treatment-emergent liver events
were not captured. Finally, subjects were not randomized
to the doses they were receiving at the time of liver events
as all would have escalated within 3 weeks to the highest
dose (120 mg/day) had they not experienced titration-lim-
iting symptoms or events. This confounds the dose:event
analysis.
6 Conclusions
In the pivotal TEMPO 3:4 clinical trial and its open-label
extension, an imbalance in the number of subjects experi-
encing serum ALT elevations exceeding 3 9 ULN was
observed. The risk of liver failure in ADPKD patients
receiving long-term tolvaptan therapy was estimated to be
approximately 1:4000, with the latency of onset occurring
primarily between 3 and 18 months of receiving therapy.
Among the positively adjudicated cases, there were no
reports of liver failure and all subjects experiencing hepatic
injury recovered. Of note, the liver safety risk for tolvap-
tan-treated subjects in the ADPKD population was not
evident in the tolvaptan-treated subjects in the non-
ADPKD population, possibly due to enhanced suscepti-
bility in the ADPKD population.
To further reduce the risk of liver injury in patients
receiving long-term tolvaptan, we recommend frequent
monitoring of liver function tests.
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